Last reviewed · How we verify
Peri-operative chemotherapy — Competitive Intelligence Brief
phase 3
Oncology
Small molecule
Live · refreshed every 30 min
Target snapshot
Peri-operative chemotherapy (Peri-operative chemotherapy) — The First Affiliated Hospital with Nanjing Medical University. Peri-operative chemotherapy administers cytotoxic chemotherapy drugs before and/or after surgical resection to eliminate micrometastatic disease and improve overall survival in cancer patients.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Peri-operative chemotherapy TARGET | Peri-operative chemotherapy | The First Affiliated Hospital with Nanjing Medical University | phase 3 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Peri-operative chemotherapy CI watch — RSS
- Peri-operative chemotherapy CI watch — Atom
- Peri-operative chemotherapy CI watch — JSON
- Peri-operative chemotherapy alone — RSS
Cite this brief
Drug Landscape (2026). Peri-operative chemotherapy — Competitive Intelligence Brief. https://druglandscape.com/ci/peri-operative-chemotherapy. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab